Skip to main content

Table 2 Hazard ratios (HRs) of mortality, and corresponding 95% confidence intervals (CIs), according to selected clinical and pathological characteristics, among 841 triple-negative breast cancers (TNBCs). Sardinia, Italy 1994–2015

From: Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients

   Number of deaths (%) HRa (95% CI) HRb (95% CI)
Tumor histotype
 Ductal invasive carcinoma 625 106 (16.9) 1.00c 1.00c
 Lobular carcinoma 65 14 (21.2) 1.04 (0.59–1.84) 0.66 (0.31–1.42)
 Other carcinomasd 104 12 (11.9) 0.56 (0.30–1.02) 0.40 (0.21–0.76)
Histologic grade
 1,2 180 40 (22.2) 1.00c 1.00c
 3 600 102 (17.0) 1.12 (0.77–1.63) 0.96 (0.58–1.58)
Tumor size (T)
 T1 309 30 (9.7) 1.00c 1.00c
 T2 364 67 (18.4) 2.71 (1.74–4.23) 2.41 (1.40–4.15)
 T3 55 13 (23.6) 2.85 (1.46–5.55) 2.24 (1.00–5.06)
 T4 43 17 (39.5) 8.13 (4.44–14.9) 5.13 (2.21–11.9)
Pathological lymph nodes (pN)
 pN0 439 39 (8.9) 1.00c 1.00c
 pN1 185 42 (22.7) 2.63 (1.69–4.10) 2.04 (1.22–3.40)
 pN2 88 21 (23.9) 3.54 (2.06–6.06) 3.11 (1.70–5.68)
 pN3 46 19 (41.3) 6.10 (3.44–10.8) 3.18 (1.51–6.71)
Distant metastases (M)
 M0 747 117 (15.7) 1.00c 1.00c
 M1 10 7 (70.0) 6.01 (2.72–13.3) 5.13 (1.69–15.6)
Tumor stagee
 I 211 11 (5.2) 1.00c 1.00c
 II 359 48 (13.4) 3.09 (1.59–6.00) 3.13 (1.56–6.27)
 III 161 52 (32.3) 9.68 (5.02–18.7) 9.65 (4.66–20.0)
 IV 10 7 (70.0) 19.8 (7.54–51.9) 29.0 (9.65–86.9)
Tumor infiltrating lymphocytes (TIL)
 No 497 90 (18.1) 1.00c 1.00c
 Yes 283 40 (14.1) 1.24 (0.85–1.80) 1.20 (0.76–1.91)
Lymphovascular invasion (LVI)
 No 587 82 (14.0) 1.00c 1.00c
 Yes 193 48 (24.9) 2.45 (1.71–3.51) 1.49 (0.93–2.38)
Necrosis
 No 480 71 (14.8) 1.00c 1.00c
 Yes 301 60 (19.9) 1.58 (1.11–2.24) 1.61 (1.03–2.51)
Ki-67 (%)
 0–15 112 19 (17.0) 1.00c 1.00c
 16–25 95 31 (32.6) 2.15 (1.21–3.83) 2.19 (1.03–4.66)
 26–35 122 24 (19.7) 1.45 (0.79–2.65) 1.65 (0.71–3.84)
 36–45 100 18 (18.0) 1.46 (0.76–2.80) 1.69 (0.70–4.09)
  ≥ 46 376 57 (15.2) 2.00 (1.14–3.51) 2.37 (1.08–5.21)
  1. aEstimates from multivariate proportional hazard regression models adjusted for study center and age at diagnosis. Estimates in bold are those significant at the 0.05 level. bEstimates further adjusted for TNM-T, TNM-N, TNM-M, necrosis, LVI, and Ki-67. cReference category. dIncluding medullary, apocrine, pleomorphic, and metaplastic carcinomas. eEstimates not adjusted for TNM-T, TNM-N, and TNM-M